Citations (78)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Nozomu Tanji, Akira Ozawa, Tadahiko Kikugawa, Noriyoshi Miura, Toyokazu Sasaki, Kouji Azuma & Masayoshi Yokoyama. (2011) Potential of histone deacetylase inhibitors for bladder cancer treatment. Expert Review of Anticancer Therapy 11:6, pages 959-965.
Read now
Read now
Tapan M Kadia & Guillermo Garcia-Manero. (2008) Role of epigenetic therapy in myelodysplastic syndrome. Expert Review of Hematology 1:2, pages 161-174.
Read now
Read now
Ehab Atallah & Guillermo Garcia-Manero. (2008) Treatment Strategies in Myelodysplastic Syndromes. Cancer Investigation 26:2, pages 208-216.
Read now
Read now
Sith Sathornsumetee & Jeremy N Rich. (2006) New treatment strategies for malignant gliomas. Expert Review of Anticancer Therapy 6:7, pages 1087-1104.
Read now
Read now
Articles from other publishers (74)
Michał Bereza, Mateusz Dembiński, Agnieszka E. Zając, Jakub Piątkowski, Monika Dudzisz-Śledź, Piotr Rutkowski & Anna M. Czarnecka. (2023) Epigenetic Abnormalities in Chondrosarcoma. International Journal of Molecular Sciences 24:5, pages 4539.
Crossref
Crossref
Guillermo Garcia-Manero. (2023) Current status of phase 3 clinical trials in high-risk myelodysplastic syndromes: pitfalls and recommendations. The Lancet Haematology 10:1, pages e71-e78.
Crossref
Crossref
Nathalie Acevedo, Bilal Alashkar Alhamwe, Luis Caraballo, Mei Ding, Antonio Ferrante, Holger Garn, Johan Garssen, Charles S. Hii, James Irvine, Kevin Llinás-Caballero, Juan Felipe López, Sarah Miethe, Khalida Perveen, Elke Pogge von Strandmann, Milena Sokolowska, Daniel P. Potaczek & Betty C. A. M. van Esch. (2021) Perinatal and Early-Life Nutrition, Epigenetics, and Allergy. Nutrients 13:3, pages 724.
Crossref
Crossref
Huanran Sun, Jiaqi Song, Mingming Sun & Changliang Shan. 2021. Epigenetic Regulation in Overcoming Chemoresistance. Epigenetic Regulation in Overcoming Chemoresistance
25
39
.
Hani Harb, James Irvine, Manori Amarasekera, Charles S. Hii, Dörthe A. Kesper, YueFang Ma, Nina D’Vaz, Harald Renz, Daniel P. Potaczek, Susan L. Prescott & Antonio Ferrante. (2017) The role of PKCζ in cord blood T-cell maturation towards Th1 cytokine profile and its epigenetic regulation by fish oil. Bioscience Reports 37:2.
Crossref
Crossref
Yu Qin, Xuejiao Zhao & Yong Fang. (2014) PP242 Synergizes With Suberoylanilide Hydroxamic Acid to Inhibit Growth of Ovarian Cancer Cells. International Journal of Gynecologic Cancer 24:8, pages 1373-1380.
Crossref
Crossref
Ying Cui, Frederick Hausheer, Robert Beaty, Cynthia Zahnow, Jean Pierre Issa, Frederick Bunz & Stephen B. Baylin. (2014) A Recombinant Reporter System for Monitoring Reactivation of an Endogenously DNA Hypermethylated Gene. Cancer Research 74:14, pages 3834-3843.
Crossref
Crossref
Björn Hackanson & Michael Daskalakis. 2014. Small Molecules in Oncology. Small Molecules in Oncology
269
297
.
Michael Daskalakis, Tina E. Joeckel, Michael Lübbert & A. Kuendgen. 2014. Epigenetic Therapy of Cancer. Epigenetic Therapy of Cancer
145
170
.
Swathi Ramakrishnan & Roberto Pili. (2013) Histone Deacetylase Inhibitors and Epigenetic Modifications as a Novel Strategy in Renal Cell Carcinoma. The Cancer Journal 19:4, pages 333-340.
Crossref
Crossref
Himashinie V.K. Diyabalanage, Michael L. Granda & Jacob M. Hooker. (2013) Combination therapy: Histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer. Cancer Letters 329:1, pages 1-8.
Crossref
Crossref
Guillermo Garcia-Manero. (2012) Can we improve outcomes in patients with acute myelogenous leukemia? Incorporating HDAC inhibitors into front-line therapy. Best Practice & Research Clinical Haematology 25:4, pages 427-435.
Crossref
Crossref
Keqin Kathy Li, Cheng Luo, Dongxia Wang, Hualiang Jiang & Y. George Zheng. (2012) Chemical and biochemical approaches in the study of histone methylation and demethylation. Medicinal Research Reviews 32:4, pages 815-867.
Crossref
Crossref
William Stevenson & Guillermo Garcia-Manero. 2013. Childhood Leukemias. Childhood Leukemias
239
256
.
Elena Menegola, Graziella Cappelletti & Francesca Di Renzo. 2012. Developmental Toxicology. Developmental Toxicology
373
383
.
Sophie Dimicoli, Elias Jabbour, Gautam Borthakur, Tapan Kadia, Zeev Estrov, Hui Yang, Mary Kelly, Sherry Pierce, Hagop Kantarjian & Guillermo Garcia‐Manero. (2011) Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate‐1 risk myelodysplastic syndrome. American Journal of Hematology 87:1, pages 127-129.
Crossref
Crossref
Brahma N Singh, Hongyuan Zhou, Jinping Li, Tracy Tipton, Bin Wang, Guo Shao, E Nickolas Gilbert, Qiang Li & Shi-Wen Jiang. (2011) Preclinical studies on histone deacetylase inhibitors as therapeutic reagents for endometrial and ovarian cancers. Future Oncology 7:12, pages 1415-1428.
Crossref
Crossref
Ali Al-Ameri, Mohamad Cherry, Guillermo Garcia-Manero & Alfonso Quintás-Cardama. (2011) Standard Therapy for Patients With Myelodysplastic Syndromes. Clinical Lymphoma Myeloma and Leukemia 11:4, pages 303-313.
Crossref
Crossref
Lijun Tan, Roland P. Kwok, Abhishek Shukla, Malti Kshirsagar, Lili Zhao, Anthony W. OpipariJrJr & J. Rebecca Liu. (2011) Trichostatin A restores Apaf-1 function in chemoresistant ovarian cancer cells. Cancer 117:4, pages 784-794.
Crossref
Crossref
Haneen Al-Azzawi, Kiren Yacqub-Usman, Alan Richardson, Leo J. Hofland, Richard N. Clayton & William E. Farrell. (2011) Reversal of Endogenous Dopamine Receptor Silencing in Pituitary Cells Augments Receptor-Mediated Apoptosis. Endocrinology 152:2, pages 364-373.
Crossref
Crossref
Stephen P. Higgins, Craig E. Higgins & Paul J. Higgins. (2011)
PAI-1 Expression Is Required for HDACi-Induced Proliferative Arrest in
ras
-Transformed Renal Epithelial Cells
. International Journal of Cell Biology 2011, pages 1-8.
Crossref
Crossref
Guillermo Garcia-Manero. 2011. The Myelodysplastic Syndromes. The Myelodysplastic Syndromes
219
238
.
William L. Carroll, Mignon Loh, Andrea Biondi & Cheryl Willman. 2011. Childhood Leukemia. Childhood Leukemia
29
61
.
Susan C. Modesitt & Sarah J. Parsons. (2010) In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: Does timing matter?. Gynecologic Oncology 119:2, pages 351-357.
Crossref
Crossref
Nuor Jamil, Sarah Howie & Donald M. Salter. (2010) Therapeutic molecular targets in human chondrosarcoma. International Journal of Experimental Pathology 91:5, pages 387-393.
Crossref
Crossref
Bing Liu, Kohshi Ohishi, Kentaro Yamamura, Kei Suzuki, Fumihiko Monma, Kazuko Ino, Masahiro Masuya, Takao Sekine, Yuji Heike, Yoichi Takaue & Naoyuki Katayama. (2010) A potential activity of valproic acid in the stimulation of interleukin-3−mediated megakaryopoiesis and erythropoiesis. Experimental Hematology 38:8, pages 685-695.
Crossref
Crossref
Tapan M. Kadia, Hui Yang, Alessandra Ferrajoli, Sirisha Maddipotti, Claudia Schroeder, Timothy L. Madden, Julianne L. Holleran, Merrill J. Egorin, Farhad Ravandi, Deborah A. Thomas, Willie Newsome, Blanca Sanchez-Gonzalez, James A. Zwiebel, Igor Espinoza-Delgado, Hagop M. Kantarjian & Guillermo Garcia-Manero. (2010) A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. British Journal of Haematology, pages no-no.
Crossref
Crossref
Yin-dong KANG & Li-ming WANG. (2010) Immunosuppressive function of histone deacetylases inhibitors:recent progress. Academic Journal of Second Military Medical University 29:1, pages 80-83.
Crossref
Crossref
Emily Ho & Roderick H. Dashwood. (2010) Dietary Manipulation of Histone Structure and Function. Journal of Nutrigenetics and Nutrigenomics 3:4-6, pages 231-238.
Crossref
Crossref
Charles S. DietrichIIIIII, Victoria L. Greenberg, Christopher P. DeSimone, Susan C. Modesitt, John R. van Nagell, Rolf Craven & Stephen G. Zimmer. (2010) Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines. Gynecologic Oncology 116:1, pages 126-130.
Crossref
Crossref
Bryan D. Young & Eric N. Olson. 2010. Heart Development and Regeneration. Heart Development and Regeneration
715
727
.
Michael Daskalakis, Nadja Blagitko-Dorfs & Björn Hackanson. 2010. Small Molecules in Oncology. Small Molecules in Oncology
131
157
.
Keqin Kathy Li, Cheng Luo, Dongxia Wang, Hualiang Jiang & Y. George Zheng. (2010) Chemical and biochemical approaches in the study of histone methylation and demethylation. Medicinal Research Reviews, pages n/a-n/a.
Crossref
Crossref
Guillermo Garcia-Manero. (2009) Progress in Myelodysplastic Syndromes. Clinical Lymphoma and Myeloma 9, pages S286-S292.
Crossref
Crossref
. 2009. Nutrients and Epigenetics. Nutrients and Epigenetics
207
227
.
Suzanne E. Wardell, Olga R. Ilkayeva, Heather L. Wieman, Daniel E. Frigo, Jeffrey C. Rathmell, Christopher B. Newgard & Donald P. McDonnell. (2009) Glucose Metabolism as a Target of Histone Deacetylase Inhibitors. Molecular Endocrinology 23:3, pages 388-401.
Crossref
Crossref
Guillermo Garcia-Manero, Hui Yang, Shao-Qing Kuang, Susan O'Brien, Deborah Thomas & Hagop Kantarjian. (2009) Epigenetics of Acute Lymphocytic Leukemia. Seminars in Hematology 46:1, pages 24-32.
Crossref
Crossref
Karen J. Marcus & Daphne Haas-Kogan. 2009. Oncology of Infancy and Childhood. Oncology of Infancy and Childhood
241
255
.
Shiyu Song, Paul Dent & Steven Grant. 2009. The Impact of Tumor Biology on Cancer Treatment and Multidisciplinary Strategies. The Impact of Tumor Biology on Cancer Treatment and Multidisciplinary Strategies
191
219
.
Guillermo Garcia-Manero. (2008) Demethylating agents in myeloid malignancies. Current Opinion in Oncology 20:6, pages 705-710.
Crossref
Crossref
Phillip H. Kuo, Kacie R. Carlson, Inger Christensen, Michael Girardi & Peter W. Heald. (2008) FDG-PET/CT for the Evaluation of Response to Therapy of Cutaneous T-cell Lymphoma to Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in a Phase II Trial. Molecular Imaging and Biology 10:6, pages 306-314.
Crossref
Crossref
Sonia Mulero-Navarro & Manel Esteller. (2008) Epigenetic biomarkers for human cancer: The time is now. Critical Reviews in Oncology/Hematology 68:1, pages 1-11.
Crossref
Crossref
Jean-Pierre Issa. (2008) Cancer Prevention: Epigenetics Steps Up to the Plate. Cancer Prevention Research 1:4, pages 219-222.
Crossref
Crossref
Liping Han, Yun Zhong, Binlu Huang, Limei Han, Lina Pan, Xin Xu, Xiuli Wang, Baiqu Huang & Jun Lu. (2008) Sodium butyrate activates erythroid-specific 5-aminolevulinate synthase gene through Sp1 elements at its promoter. Blood Cells, Molecules, and Diseases 41:2, pages 148-153.
Crossref
Crossref
William C. Kisseberth, Sridhar Murahari, Cheryl A. London, Samuel K. Kulp & Ching-Shih Chen. (2008) Evaluation of the effects of histone deacetylase inhibitors on cells from canine cancer cell lines. American Journal of Veterinary Research 69:7, pages 938-945.
Crossref
Crossref
Claire Bonfils, Ann Kalita, Marja Dubay, Lillian L. Siu, Michael A. Carducci, Gregory Reid, Robert E. Martell, Jeffrey M. Besterman & Zuomei Li. (2008) Evaluation of the Pharmacodynamic Effects of MGCD0103 from Preclinical Models to Human Using a Novel HDAC Enzyme Assay. Clinical Cancer Research 14:11, pages 3441-3449.
Crossref
Crossref
Tadhg P. BegleyKE Hauschild, CD Carlson, LJ Donato, R Moretti & AZ Ansari. 2007. Wiley Encyclopedia of Chemical Biology. Wiley Encyclopedia of Chemical Biology.
Matthias Körner & Ulrich Tibes. 2008. Progress in Medicinal Chemistry Volume 46. Progress in Medicinal Chemistry Volume 46
205
280
.
Arturo J. Vegas, James E. Bradner, Weiping Tang, Olivia M. McPherson, Edward F. Greenberg, Angela N. Koehler & Stuart L. Schreiber. (2007) Fluorous‐Based Small‐Molecule Microarrays for the Discovery of Histone Deacetylase Inhibitors. Angewandte Chemie International Edition 46:42, pages 7960-7964.
Crossref
Crossref
Arturo J. Vegas, James E. Bradner, Weiping Tang, Olivia M. McPherson, Edward F. Greenberg, Angela N. Koehler & Stuart L. Schreiber. (2007) Fluorous‐Based Small‐Molecule Microarrays for the Discovery of Histone Deacetylase Inhibitors. Angewandte Chemie 119:42, pages 8106-8110.
Crossref
Crossref
Sharon A Ross & John A Milner. (2007) Epigenetic modulation and cancer: effect of metabolic syndrome?. The American Journal of Clinical Nutrition 86:3, pages 872S-877S.
Crossref
Crossref
Luca Sigalotti, Elisabetta Fratta, Sandra Coral, Enzo Cortini, Alessia Covre, Hugues J.M. Nicolay, Lucia Anzalone, Laura Pezzani, Anna Maria Di Giacomo, Ester Fonsatti, Francesca Colizzi, Maresa Altomonte, Luana Calabrò & Michele Maio. (2007) Epigenetic drugs as pleiotropic agents in cancer treatment: Biomolecular aspects and clinical applications. Journal of Cellular Physiology 212:2, pages 330-344.
Crossref
Crossref
S.W. Choy, Y.M. Wong, S.H. Ho & K.L. Chow. (2007) C. elegans SIN-3 and its associated HDAC corepressor complex act as mediators of male sensory ray development. Biochemical and Biophysical Research Communications 358:3, pages 802-807.
Crossref
Crossref
Nelli G. Markova, Nevena Karaman-Jurukovska, Adriana Pinkas-Sarafova, Liuben N. Marekov & Marcia Simon. (2007) Inhibition of Histone Deacetylation Promotes Abnormal Epidermal Differentiation and Specifically Suppresses the Expression of the Late Differentiation Marker Profilaggrin. Journal of Investigative Dermatology 127:5, pages 1126-1139.
Crossref
Crossref
Claude Monneret. (2007) Histone deacetylase inhibitors for epigenetic therapy of cancer. Anti-Cancer Drugs 18:4, pages 363-370.
Crossref
Crossref
Amy L. Cooper, Victoria L. Greenberg, Pamela S. Lancaster, John R. van NagellJr.Jr., Stephen G. Zimmer & Susan C. Modesitt. (2007) In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer. Gynecologic Oncology 104:3, pages 596-601.
Crossref
Crossref
Alexander Kamb, Susan Wee & Christoph Lengauer. (2006) Why is cancer drug discovery so difficult?. Nature Reviews Drug Discovery 6:2, pages 115-120.
Crossref
Crossref
Stefan Kubicek, Roderick J. O'Sullivan, E. Michael August, Eugene R. Hickey, Qiang Zhang, Miguel L. Teodoro, Stephen Rea, Karl Mechtler, Jennifer A. Kowalski, Carol Ann Homon, Terence A. Kelly & Thomas Jenuwein. (2007) Reversal of H3K9me2 by a Small-Molecule Inhibitor for the G9a Histone Methyltransferase. Molecular Cell 25:3, pages 473-481.
Crossref
Crossref
Guillermo Garcia-Manero. (2007) Modifying the Epigenome as a Therapeutic Strategy in Myelodysplasia. Hematology 2007:1, pages 405-411.
Crossref
Crossref
Riku Sakimura, Kazuhiro Tanaka, Syunsaku Yamamoto, Tomoya Matsunobu, Xu Li, Masuo Hanada, Takamitsu Okada, Tomoyuki Nakamura, Yang Li & Yukihide Iwamoto. (2007) The Effects of Histone Deacetylase Inhibitors on the Induction of Differentiation in Chondrosarcoma Cells. Clinical Cancer Research 13:1, pages 275-282.
Crossref
Crossref
U.P. Kelavkar, N.S. Harya, J. Hutzley, D.J. Bacich, F.A. Monzon, U. Chandran, R. Dhir & D.S. O’Keefe. (2007) DNA methylation paradigm shift: 15-Lipoxygenase-1 upregulation in prostatic intraepithelial neoplasia and prostate cancer by atypical promoter hypermethylation. Prostaglandins & Other Lipid Mediators 82:1-4, pages 185-197.
Crossref
Crossref
V. Swaminathan, B.A. Ashok Reddy, Ruthrotha Selvi B, Sukanya M.S.Tapas K. Kundu. 2007. Chromatin and Disease. Chromatin and Disease
399
418
.
Michelle D. Williams, Nitin Chakravarti, Merrill S. Kies, Shin-Ichiro Maruya, Jeffrey N. Myers, Joie C. Haviland, Randal S. Weber, Reuben Lotan & Adel K. El-Naggar. (2006) Implications of Methylation Patterns of Cancer Genes in Salivary Gland Tumors. Clinical Cancer Research 12:24, pages 7353-7358.
Crossref
Crossref
Elena Menegola, Francesca Di Renzo, Maria Luisa Broccia & Erminio Giavini. (2006) Inhibition of histone deacetylase as a new mechanism of teratogenesis. Birth Defects Research Part C: Embryo Today: Reviews 78:4, pages 345-353.
Crossref
Crossref
Guillermo Garcia-ManeroHagop M. KantarjianBlanca Sanchez-GonzalezHui YangGary RosnerSrdan VerstovsekMichael RyttingWilliam G. WierdaFarhad RavandiCharles KollerLianchun XiaoStefan FaderlZeev EstrovJorge CortesSusan O'BrienElihu EsteyCarlos Bueso-RamosJackie FiorentinoElias JabbourJean-Pierre Issa. (2006) Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 108:10, pages 3271-3279.
Crossref
Crossref
Elihu Estey & Hartmut D?hner. (2006) Acute myeloid leukaemia. The Lancet 368:9550, pages 1894-1907.
Crossref
Crossref
Annie Hurtubise & Richard L. Momparler. (2006) Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2′-deoxycytidine (decitabine) on human breast carcinoma cells. Cancer Chemotherapy and Pharmacology 58:5, pages 618-625.
Crossref
Crossref
Blanca Sanchez-GonzalezHui YangCarlos Bueso-RamosKoyu HoshinoAlfonso Quintas-CardamaVictoria M. RichonGuillermo Garcia-Manero. (2006) Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. Blood 108:4, pages 1174-1182.
Crossref
Crossref
Thomas Jenuwein. (2006) The epigenetic magic of histone lysine methylation. The FEBS Journal 273:14, pages 3121-3135.
Crossref
Crossref
Jonathan D. Walton. (2006) HC-toxin. Phytochemistry 67:14, pages 1406-1413.
Crossref
Crossref
Latha Shivakumar, Chris Schwab, Brian L. Abbott, Sundar Jagannath & Thomas Lin. (2006) Highights From: 47th Annual Meeting of the American Society of Hematology, December 2005, Atlanta, GA. Clinical Lymphoma and Myeloma 6:6, pages 448-454.
Crossref
Crossref
Sabeeha Muneer, G. Kesava Reddy, Aarati Ranganathan, Latha Shivakumar, Oliver Sartor & Vinay K. Jain. (2006) Highlights from The 2006 American Society of Clinical Oncology Prostate Cancer Symposium; San Francisco, CA; February 24-26, 2006. Clinical Genitourinary Cancer 4:4, pages 240-245.
Crossref
Crossref
Latha Shivakumar, Chris Schwab, Brian L. Abbott, Sundar Jagganath & Thomas Lin. (2006) Highlights From: 47th Annual Meeting of the American Society of Hematology, Atlanta, GA, December 10–13, 2005. Clinical Lymphoma and Myeloma 6:5, pages 358-364.
Crossref
Crossref
Guillermo Garcia-Manero & Steven D. Gore. (2005) Future Directions for the Use of Hypomethylating Agents. Seminars in Hematology 42, pages S50-S59.
Crossref
Crossref